Veru Inc. (VERU:NASDAQ) closed at $2.12 on November 10, 2026, down 3.20% on the day. The stock trades 71.1% below its 52-week high of $7.33 and 3.9% above its 52-week low of $2.04. Over the past year, it lost 19.1%. Veru Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 10, 2025, VERU closed higher on 121 days (48%). Its best day was June 4, 2026 (+88.00%) and its worst was June 5, 2026 (-19.62%). The stock moved 10% or more in a single session 8 times.
The Female Health Company, a medical therapeutics company, develops, manufactures, and markets consumer health care products. The company's pharmaceuticals product portfolio includes Tamsulosin delayed release sachet that is under bioequivalence study for the treatment of benign prostatic hyperplasia; MSS-722, a fixed ratio of trans- and cis-clomiphene citrate isomers, which is under the Phase II clinical trial to treat male infertility caused by testicular dysfunction; APP-944, a zuclomiphene citrate that is under the Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and APP-111, an oral tubulin targeting chemotherapy, which is under the preclinical study to treat metastatic prostate, breast, and ovarian cancers, as well as APP-111/112 oral agents that target colchicine binding site of tubulin for the treatment of gout and familial mediterranean fever. It also provides consumer health and medical devices, including PREBOOST benzocaine wipes for premature ejaculation; and FC2, which is female disposable contraceptive device, as well as FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/A...
Find more stocks like VERU with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.